文献速递肝病

慢性肝病及肝移植受者体外受精的安全性与有效性

Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients.
PubMed 文献 · J Hepatol · 2021-01-16

该回顾性分析纳入42例肝病相关不孕女性,1990至2019年间共57个IVF周期,其中肝硬化6例9周期、肝移植后11例14周期、无肝硬化25例34周期。43个周期成功植入,活产率74%(32/43),但需警惕OHSS、产科胆汁淤积和早产风险。

要点

  • 肝病相关不孕女性IVF活产率可达74%,但肝硬化及肝移植后患者需个体化评估。
  • IVF期间16%周期出现肝酶异常,1例AIH肝硬化患者治疗后失代偿需停药。
  • OHSS罕见(7%),但产科胆汁淤积和早产风险需提前告知。

核心结论

  • 在经选择的肝病相关不孕女性中,IVF可成功实现妊娠,但需告知OHSS、产科胆汁淤积和早产等潜在风险。

研究设计与样本

  • 回顾性分析纳入42例肝病相关不孕女性,1990至2019年间共57个IVF周期。
  • 其中肝硬化6例9周期,肝移植后11例14周期,无肝硬化25例34周期。
  • 肝病主要病因包括HBV、HCV和自身免疫性肝炎。

主要发现

  • 57个IVF周期中43个(75%)成功植入,活产率为74%(32/43)。
  • 8例流产(肝移植后2例、肝硬化3例、无肝硬化4例)。
  • 9/57(16%)周期出现新发肝酶异常,治疗结束后改善。
  • 6例妊娠合并产科胆汁淤积(肝移植后2例、无肝硬化4例)。
  • OHSS罕见(n=3,7%),1例AIH相关肝硬化患者启动IVF后失代偿需停药,无孕产妇死亡。

关键数值与推荐

  • 肝硬化患者IVF失败2/9(22%),肝移植后4/14(29%),无肝硬化6/34(18%)。
  • 3例发生妊娠期高血压疾病,半数妊娠为早产(范围27-36周)。

临床怎么用

  • 对肝病相关不孕女性提供IVF前应多学科评估,重点筛查肝硬化及肝移植后状态。
  • IVF治疗期间需监测肝酶,警惕肝病失代偿,尤其AIH相关肝硬化患者。
  • 孕前咨询应告知OHSS、产科胆汁淤积和早产风险。

局限性

  • 回顾性设计,样本量较小(42例女性57周期),数据跨1990至2019年。
  • 原文未报告对照人群及具体统计比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Chronic liver disease and liver transplantation (LT) can delay both timing and ability of women to conceive. With increased awareness and availability of in vitro fertilisation (IVF), the need for accurate counselling is paramount. To date, minimal data exist on outcomes of IVF in patients with chronic liver disease, cirrhosis, or post-LT. We report the largest experience of IVF in women with liver-related subfertility (LRSF). METHODS: A retrospective analysis was performed on 42 women with LRSF who had undergone 57 IVF cycles between 1990 and 2019. RESULTS: Forty-two women with LRSF received IVF; 9 cycles in 6 women with cirrhosis, 14 cycles in 11 women post-LT, and 34 cycles in 25 women without cirrhosis. The main aetiologies of liver disease included HBV, HCV, and autoimmune hepatitis (AIH). Of 57 IVF cycles evaluated, 43 (75%) resulted in successful implantation. Eight (2 post-LT, 3 with cirrhosis, 4 without cirrhosis) resulted in miscarriage. The live birth rate (LBR) was 74% (32/43). Two of 9 (22%) patients with cirrhosis, 4/14 (29%) patients who were post-LT, and 6/34 (18%) patients without cirrhosis had unsuccessful IVF attempts. Nine of 57 (16%) IVF cycles resulted in new liver enzyme derangement during therapy, which improved after treatment completion. Six pregnancies (2 in patients who were post-LT, 4 without cirrhosis) were complicated by obstetric cholestasis (OC). Ovarian hyperstimulation syndrome (OHSS) was rare (n = 3, 7%). One patient with AIH-related cirrhosis decompensated after initiating IVF, warranting discontinuation of therapy. There were no maternal deaths. Three women developed a hypertensive disorder of pregnancy. Half the pregnancies resulted in premature deliveries (range 27-36 weeks). CONCLUSIONS: In selected cases, IVF in women with LRSF can be successful. However, patients should be counselled on the potential increased risks of OHSS, OC, and prematurity. LAY SUMMARY: Women with liver disease or those who have had a liver transplant can experience difficulties getting pregnant. In this study, we look at whether alternative approaches to achieve pregnancy are harmful in these women. Overall, there were no significant issues with the use of in vitro fertilisation in women with liver disease, but they need to be aware of potential risks, such as early delivery of the baby.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Rahim MN, Theocharidou E, Yen Lau KG, et al. Safety and efficacy of in vitro fertilisation in patients with chronic liver disease and liver transplantation recipients. J Hepatol. 2021. PMID: 33460690. doi:10.1016/j.jhep.2020.12.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。